Heart arrhythmia and QT interval corrections
Assessing the risk of a drug candidate inducing arrhythmia is a vital step in the drug development process. Due to the difficulty of directly assessing these potential arrhythmias, researchers rely on QT interval prolongation as a biomarker for arrhythmia risk. The results showed that the corrected QT values can have reduced variability and heart rate influence when correction methods consider additional variables, such as subject specific, date specific, or environment specific differences.